SEC Form SC 13G/A filed by Aptinyx Inc. (Amendment)

$APTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $APTX alert in real time by email
SC 13G/A 1 aptinyx13gamd1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)

 

 

Aptinyx Inc.

(Name of Issuer)

 

 

Common Stock, par value $0.01

(Title of Class of Securities)

 

 

03836N103

(CUSIP Number)

 

 

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[ ]       Rule 13d-1(b)

 

[X]       Rule 13d-1(c)

 

[ ]       Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 1 

CUSIP NO. 03836N103

 

 

1.Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

John A. Kryzanowski

 

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ______

(b) ______

 

3. SEC Use Only

 

4.Citizenship or Place of Organization United States

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power             1,942,680

6. Shared Voting Power 0

 

7. Sole Dispositive Power             1,942,680
8. Shared Dispositive Power                             0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,942,680

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 5.77%*

 

12.Type of Reporting Person (See Instructions)

 

IN

 

 

 

* Percentage calculated based on shares of common stock outstanding on November 8, 2019, as reported on the Form 10-Q for the quarterly period ended September 30, 2019, by Aptinyx Inc.

 

 

 2 

CUSIP NO. 03836N103

Item 1.

 

(a)Name of Issuer

Aptinx Inc.

 

(b)Address of Issuer's Principal Executive Offices

909 Davis Street, Suite 600
Evanston, IL 60201

 

Item 2.

 

(a) The names of the person filing this statement is:

John A. Kryzanowski


(the "Filer").

 

(b)The principal business office of the Filer is located at:

c/o Shartsis Friese LLP
One Maritime Plaza, 18th Floor
San Francisco, CA 94111

 

(c)For citizenship of the Filer, see Item 4 of the cover sheet for the Filer.

 

(d)This statement relates to shares of common stock of the Issuer (the "Stock").

 

(e)The CUSIP number of the Issuer is: 03836N103
 3 

CUSIP NO. 03836N103

Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

(e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

 

(f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

 

(g)[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

 

(h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

 

(i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

 

(j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

 

 

Item 4.Ownership.

 

See Items 5-9 and 11 of the cover page for the Filer.

 

Item 5.Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

The Filer does not have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock held by any other person, except for members of the Filer’s immediate family or trusts controlled by the Filer. To the Filer's knowledge, no holdings of the Stock of any such family member or trust are more than five percent of the outstanding Stock.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 4 

CUSIP NO. 03836N103

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.Notice of Dissolution of Group

 

Not applicable.

 

Item 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: June 23, 2022

 

 

/s/ John A. Kryzanowski

 

 

 

 

 

Get the next $APTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APTX

DatePrice TargetRatingAnalyst
4/7/2022Outperform → Mkt Perform
William Blair
12/20/2021$12.00 → $10.00Outperform
SVB Leerink
More analyst ratings

$APTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

    Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi

    $APTX
    $BAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
  • Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

    Aptinyx Inc. (NASDAQ:APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, Aptinyx completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disorder (PTSD). The study was halted in February prior to its completion in support of the company's preservation of capital. In the analysis, NYX-783 did not demonstrate sufficient improvement on the study's primary endpoint to support continued advancement of the development program by Aptinyx. In March, Aptinyx engaged Ladenburg Thalmann as its exclusive fi

    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

    NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company will terminate its ongoing study of NYX-783 in PTSD and analyze the data available to date Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies. Across the overall study population, NYX-

    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$APTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$APTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$APTX
SEC Filings

See more

$APTX
Leadership Updates

Live Leadership Updates

See more
  • Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

    Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi

    $APTX
    $BAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
  • Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of directors. Dr. O'Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. "Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors," said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. "His expertise in research and clinical development is amplified by the successful development programs he has overseen across a rang

    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company's Board of Directors. Dr. Miller currently serves as the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School, as well as Chief of Ophthalmology at both Massachusetts Eye and Ear and Massachusetts General Hospital, and Ophthalmologist-in-Chief at Brigham and Women's Hospital. "We are delighted to welcome Joan to the Aptinyx Board of Directors," said Norbert Riedel, Ph.D., chief executive offic

    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$APTX
Financials

Live finance-specific insights

See more
  • Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

    Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor

    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

    Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx'

    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights

     Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder $85 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the

    $APTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$APTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more